Skip to main content

The LLS Blog

Read about survivors, research, fundraising and advocacy.

FDA Approves First CAR T-Immunotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia

The U.S. Food and Drug Administration (FDA) recently announced approval of brexucabtagene autoleucel (Tecartus®) as the first and only CAR T-cell treatment for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).

LLS makes progress for blood cancer patients through virtual advocacy

Learn how LLS is making an impact through virtual advocacy efforts that put patients and families first. 

FDA APPROVES NEW CHEMOTHERAPY COMPONENT FOR MOST COMMON CHILDHOOD CANCER

The U.S. Food and Drug Administration (FDA) yesterday approved asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze™) as a component of a chemotherapy regimen used to treat acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in patients who are allergic to other commonly used asparaginase products. ALL is the most common type of childhood cancer, with nearly 3,000 new cases diagnosed each year in the U.S.

Highlights from ASCO 2021

The 2021 American Society of Clinical Oncology (ASCO) Annual Meeting took place last week. ASCO brings together the cancer community to explore the latest advancements in research, treatment and patient care.  

The theme of this year's meeting was “Equity: Every Patient. Every Day. Everywhere.” We were particularly gratified to see this topic because as a patient-focused organization, The Leukemia & Lymphoma Society (LLS) stands for all cancer patients, working to ensure they have access to quality affordable care.

Older Posts